Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha-1 after curative resection for HBV-related small hepatocellular carcinoma
ChiCTR1800014409Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2018
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thymosin alpha 1 in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: 1-, 3-, and 5-year recurrence-free survival and Tumor recurrence. Started Jan 2018; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR1800014409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014409.